The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats

American Journal of Pathology

Volumn 185, Issue 2, 2015, Pages 409-419

  Verbeke, Len ^a   Farre, Ricard ^b,e   Verbinnen, Bert ^c,f   Covens, Kris ^c   Vanuytsel, Tim ^b   Verhaegen, Jan ^d   Komuta, Mina ^a   Roskams, Tania ^a   Chatterjee, Sagnik ^a   Annaert, Pieter ^a   Elst, Ingrid Vander ^a   Windmolders, Petra ^a   Trebicka, Jonel ^g   Nevens, Frederik ^a   Laleman, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d REGA INSTITUTE   (Belgium)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Thomas More University College   (Belgium)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 2; CYTOKINE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; GAMMA INTERFERON; OBETICHOLIC ACID; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; 6-ETHYLCHENODEOXYCHOLIC ACID; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL TRANSLOCATION; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; ILEUM; IN VITRO STUDY; INFANT; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; LIVER INJURY; MALE; MESENTERY LYMPH NODE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BACTERIAL TRANSLOCATION; CHENODEOXYCHOLIC ACID; CHOLESTASIS; CYTOKINES; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; ILEUM; MALE; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84922397855     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.10.009     Document Type: Article

References (53)

1. Berg RD, Garlington AW: Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979, 23:403-411
2. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB: Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995, 108:1835-1841
3. Garcia-Tsao G, Albillos A, Barden GE, West AB: Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993, 17:1081-1085
4. Llovet JM, Bartolí R, Planas R, Cabré E, Jimenez M, Urban A, Ojanguren I, Arnal J, Gassull MA: Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut 1994, 35:1648-1652
5. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J: Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001, 34:32-37
6. Verbeke L, Nevens F, Laleman W: Bench-to-beside review: acute-onchronic liver failure - linking the gut, liver and systemic circulation. Crit Care 2011, 15:233
7. Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, Verslype C, Nevens F: Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011, 5:523-537. quiz 537
8. Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J: Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010, 52: 2044-2052
9. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASLeCLIF Consortium: Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013, 144:1426-1437. 1437.e1-e9
10. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F: Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010, 59:1561-1569
11. Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, Augustin S, Mookerjee RP, Michelena J, Smyrk TC, Buob D, Leteurtre E, Rincón D, Ruiz P, García-Pagán JC, Guerrero-Marquez C, Jones PD, Barritt AS, Arroyo V, Bruguera M, Bañares R, Ginès P, Caballería J, Roskams T, Nevens F, Jalan R, Mathurin P, Shah VH, Bataller R: A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014, 146:1231-1239. e1-e6
12. Kuzu MA, Kale IT, Cöl C, Tekeli A, Tanik A, Köksoy C: Obstructive jaundice promotes bacterial translocation in humans. Hepatogastroenterology 1999, 46:2159-2164
13. Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR, Girona E, Gutiérrez A, Carnices F, Palazón JM, Sola-Vera J, Pérez-Mateo M: Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003, 50:1482-1486
14. Zuckerman MJ, Menzies IS, Ho H, Gregory GG, Casner NA, Crane RS, Hernandez JA: Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. Dig Dis Sci 2004, 49:621-626
15. Du Plessis J, Vanheel H, Janssen CE, Roos L, Slavik T, Stivaktas PI, Nieuwoudt M, van Wyk SG, Vieira W, Pretorius E, Beukes M, Farré R, Tack J, Laleman W, Fevery J, Nevens F, Roskams T, Van der Merwe SW: Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol 2013, 58:1125-1132
16. Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab: Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013, 58:911-921
17. Thalheimer U, De Iorio F, Capra F, del Mar Lleo M, Zuliani V, Ghidini V, Tafi MC, Caburlotto G, Gennari M, Burroughs AK, Vantini I: Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepzatol 2010, 22:1228-1234
18. Ramos AR, Matte U, Goldani HA, Oliveira OL, Vieira SM, Silveira TR: Intestinal permeability assessed by 51Cr-EDTA in rats with CCl4-induced cirrhosis. Arq Gastroenterol 2010, 47: 188-192
19. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR: Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 2011, 73: 283-309
20. Watson CJ, Hoare CJ, Garrod DR, Carlson GL, Warhurst G: Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. J Cell Sci 2005, 118:5221-5230
21. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR: Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by upregulating myosin light chain kinase expression. Am J Pathol 2005, 166:409-419
22. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A: Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 2005, 19:923-933
23. Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G: Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology 2005, 128:1258-1267
24. Smyth D, McKay CM, Gulbransen BD, Phan VC, Wang A, McKay DM: Interferon-gamma signals via an ERK1/2-ARF6 pathway to promote bacterial internalization by gut epithelia. Cell Microbiol 2012, 14:1257-1270
25. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W: Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48:1632-1643
26. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW: Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60:463-472
27. Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, Li S: FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 2008, 77:169-177
28. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Vander Elst I, Windmolders P, Vanuytsel T, Nevens F, Laleman W: Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014, 59:2286-2298
29. Laleman W, Vander Elst I, Zeegers M, Servaes R, Libbrecht L, Roskams T, Fevery J, Nevens F: A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 2006, 36:242-249
30. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108
31. Wallon C, Braaf Y, Wolving M, Olaison G, Söderholm JD: Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon. Scand J Gastroenterol 2005, 40:586-595
32. Chatterjee S, Bijsmans IT, van Mil SW, Augustijns P, Annaert P: Toxicity and intracellular accumulation of bile acids in sandwichcultured rat hepatocytes: role of glycine conjugates. Toxicol In Vitro 2014, 28:218-230
33. Madara JL, Stafford J: Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1989, 83:724-727
34. Wiest R, Krag A, Gerbes A: Spontaneous bacterial peritonitis: recent guidelines and beyond [Erratum appeared in Gut 2012, 61:636]. Gut 2012, 61:297-310
35. Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota R, Ariza J, Xiol X: Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012, 56:825-832
36. Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forné M, Planas R, Bañares R, Castells L, Jimenez De Anta MT, Arroyo V, Rodés J: Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011-1017
37. Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W: Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009, 37: 2-8
38. Vanwijngaerden YM, Wauters J, Langouche L, Vander Perre S, Liddle C, Coulter S, Vanderborght S, Roskams T, Wilmer A, Van den Berghe G, Mesotten D: Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 2011, 54:1741-1752
39. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009, 89: 147-191
40. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stöger U, Arrese M, Pizarro M, Solís N, Carrasco G, Caligiuri A, Sombetzki M, Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H, Pinzani M, Trauner M: Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts [Erratum appeared in Am J Pathol 2010, 176:2581]. Am J Pathol 2009, 175:2392-2405
41. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013, 145: 574-582.e1
42. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012, 142:355-365. e1-4
43. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM: 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002, 45: 3569-3572
44. Vanwijngaerden YM, Langouche L, Derde S, Liddle C, Coulter S, van den Berghe G, Mesotten D: Impact of parenteral nutrition versus fasting on hepatic bile Acid production and transport in a rabbit model of prolonged critical illness. Shock 2014, 41:48-54
45. Poupon R: Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36(Suppl 1):S3-S12
46. Neimark E, Chen F, Li X, Shneider BL: Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 2004, 40:149-156
47. Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, Guo GL: Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine [Erratum appeared in Hepatology 2010, 52:402]. Hepatology 2010, 51:1410-1419
48. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita AV, Pardon N, Santos J, Söderholm JD, Tack J, Farré R: Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 2014, 63:262-271
49. Vanuytsel T, van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S, Houben E, Salim Rasoel S, Tóth J, Holvoet L, Farré R, Van Oudenhove L, Boeckxstaens G, Verbeke K, Tack J: Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014, 63:1293-1299
50. Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, Santucci L, Fiorucci S: The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 2009, 183:6657-6666
51. Adorini L, Pruzanski M, Shapiro D: Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012, 17:988-997
52. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR: Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013, 288:11761-11770
53. Ubeda M, Borrero MJ, Lario M, Muñoz L, Conde E, Rodríguez M, LLedó L, García-Bermejo L, Álvarez-Mon M, Albillos A. The farnesoid X receptor agonist, obeticholic acid, improves intestinal antibacterial defense and reduces gut bacterial translocation and hepatic fibrogenesis in CCl4-cirrhotic rats with ascites. Abstracts of the International Liver Congress 2014; 49th Annual meeting of the European Association for the Study of the Liver. April 9-13, 2014, London, UK. J Hepatol 2014;61(1 Suppl):S63 (abstract O153)